Cytokinetics shares are trading lower by 15.8% during Thursday's session. The company announced the pricing of a public offering of 9,803,922 shares. Ready to turn the market’s comeback into steady ...
Investors in Cytokinetics Inc (Symbol: CYTK) saw new options become available today, for the December 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, ...
Barclays analyst Emily Field maintained a Buy rating on Cytokinetics today and set a price target of $87.00. Claim 70% Off TipRanks Premium. Unlock hedge fund-level data and power ...
New Analyses from Three Trials in Obstructive HCM Support Findings from Previously Published Data on MYQORZO™ (aficamten) SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, ...
Hosted on MSN
Is Cytokinetics Inc. (CYTK) Positioned for Success with Its Innovative Muscle Modulators?
We recently published a list of 7 Best Small Company Stocks To Invest In. In this article, we are going to take a look at where Cytokinetics Inc. (NASDAQ:CYTK) stands against the other best small ...
High-rolling investors have positioned themselves bearish on Cytokinetics (NASDAQ:CYTK), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga ...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options According to the ...
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the ...
We recently published a list of 10 Firms Battered by Poor Earnings, Dismal Outlook. In this article, we are going to take a look at where Cytokinetics, Inc. (NASDAQ:CYTK) stands against other Friday’s ...
Shares of Cytokinetics, Inc. (NASDAQ:CYTK) are trading sharply higher Tuesday after the biopharmaceutical company presented new data highlighting the long-term safety and efficacy of its ...
This morning, it’s probably safe to say that Steve Cohen does NOT consider himself the luckiest man on earth. In a stunning reversal of fortune, Cytokinetics (CYTK) has watched its stock plummet over ...
We recently published 10 Big Names Investors Are Dumping. Cytokinetics, Inc. (NASDAQ:CYTK) is one of the worst performers on Wednesday. Shares of Cytokinetics dropped by 4.42 percent on Wednesday to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results